What Is Semaglutide? The GLP-1 Peptide Reshaping Metabolic Research
- Durham Peptides
- Mar 18
- 3 min read
Semaglutide has become one of the most discussed compounds in modern biomedical research. Originally developed as a treatment for type 2 diabetes, it gained widespread public attention when clinical trials demonstrated significant effects on body weight reduction — leading to enormous consumer demand and a surge of interest in the underlying science.
This article covers what semaglutide is, how it works, what the published clinical research shows, and how it compares to other compounds in the same class.
What Is Semaglutide?
Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone produced in the gut. GLP-1 plays a central role in glucose homeostasis — it is released after eating and stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and signals satiety to the brain.
Natural GLP-1 has a half-life of approximately 2-3 minutes before being degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). Semaglutide was engineered with specific amino acid modifications and a fatty acid side chain that extends its half-life to approximately 7 days, making it suitable for once-weekly administration in clinical settings.
The molecular formula is C187H291N45O59, with a molecular weight of approximately 4113.58 g/mol. CAS number: 910463-68-2.
How Semaglutide Works
Semaglutide binds to GLP-1 receptors, which are expressed in the pancreas, brain, gastrointestinal tract, and cardiovascular system. Its primary studied effects include:
Pancreatic beta cells — Semaglutide stimulates glucose-dependent insulin secretion, meaning it promotes insulin release only when blood glucose is elevated. This reduces the risk of hypoglycemia compared to some other glucose-lowering agents.
Central nervous system — GLP-1 receptors in the hypothalamus are involved in appetite regulation. Semaglutide's effects on food intake and satiety are believed to be mediated primarily through these central pathways.
Gastric motility — Like natural GLP-1, semaglutide slows gastric emptying, which contributes to prolonged feelings of fullness after eating.
Cardiovascular system — GLP-1 receptors are present in the heart and blood vessels. Cardiovascular outcome trials have been a significant component of semaglutide's clinical research profile.
What the Clinical Research Shows
Semaglutide has one of the most extensive clinical trial programs of any peptide compound:
The SUSTAIN program — A series of clinical trials that evaluated semaglutide for glycemic control in type 2 diabetes. These trials demonstrated significant reductions in HbA1c compared to placebo and active comparators.
The STEP program — A series of clinical trials evaluating semaglutide for weight management. The STEP 1 trial reported a mean body weight reduction of approximately 14.9% from baseline over 68 weeks.
SELECT trial — A cardiovascular outcome trial that evaluated the effects of semaglutide on major adverse cardiovascular events in overweight or obese adults without diabetes.
Branded vs. Research-Grade Semaglutide
In clinical settings, semaglutide is marketed under brand names for specific approved indications. Research-grade semaglutide, such as the product offered by Durham Peptides, is a lyophilized peptide supplied for in-vitro and laboratory research applications. It is not a pharmaceutical product and is not intended for human use.
Research-grade semaglutide allows scientists to study the compound's mechanisms, receptor binding characteristics, and signaling pathways in controlled laboratory environments.
How Semaglutide Compares to Other Incretin Peptides
Semaglutide is one of several incretin receptor agonists that have been developed for research and clinical use. Key distinctions include:
Semaglutide is a GLP-1 single agonist — it activates only the GLP-1 receptor.
Tirzepatide is a dual agonist, activating both GLP-1 and GIP receptors, which may produce different metabolic effects through complementary pathways.
Retatrutide is a triple agonist, activating GLP-1, GIP, and glucagon receptors simultaneously — the first compound of its kind to reach advanced clinical trials.
For a detailed comparison, see our article: Semaglutide vs Tirzepatide: What's the Difference?. For a three-way comparison, see Retatrutide vs Tirzepatide vs Semaglutide.
Product Specifications
Form: Lyophilized powder
Net weight: 10mg per vial Purity: 99%+ (HPLC verified)
Testing: Third-party verified by Janoshik Analytical
Storage: 2–8°C, protect from light and moisture
CAS: 910463-68-2
Browse the Semaglutide product page or view our full lab results.
Selected Research References
Marso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." N Engl J Med. 2016. PMID: 28930111
Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021. PMID: 33567185
Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. 2023. PMID: 37952131
All products mentioned in this article are sold by Durham Peptides for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
